Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.For the prevention of the onset of type 2 diabetes in patients with impaired glucose tolerance
Subscribe to our email newsletter
Takeda Pharmaceutical (Takeda) has received approval from the Japanese Ministry of Health, Labour and Welfare for an additional indication of Basen Tablets 0.2 and Basen OD Tablets 0.2 (generic name: voglibose, hereinafter Basen) for prevention of the onset of type 2 diabetes in patients with impaired glucose tolerance (IGT), the first of its kind in Japan.
Reportedly, this additional indication has been approved based on the clinical evidence with Japanese subjects which shows preventive effects against the onset of type 2 diabetes when Basen is administered to patients with IGT. That evidence was published in “The Lancet.”
The company has said that although dietary treatment and/or exercise therapy is conducted for IGT patients, there are cases in which sufficient effects are not attained. The new treatment option of medicinal therapy presented by BASEN is expected to prevent the onset of diabetes more effectively.